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ReviewEvolutionary conserved and pleiotropic, the TPT1/TCTP
gene (translationally controlled tumor protein, also
called HRF, fortilin), encodes a highly structured mRNA
shielded by ribonucleoproteins and closely resembling
viral particles. This mRNA activates, as do viruses, pro-
tein kinase R (PKR). The TPT1/TCTP protein is structur-
ally similar to mRNA-helicases and MSS4. TPT1/TCTP
has recently been identified as a prognostic factor in
breast cancer and a critical regulator of the tumor sup-
pressor p53 and of the cancer stem cell (SC) compart-
ment. Emerging evidence indicates that TPT1/TCTP is
key to phenotypic reprogramming, as shown in the
process of tumor reversion and possibly in pluripotency.
We provide here an overview of these diverse functions
of TPT1/TCTP.
Initial discoveries
As many proteins of unknown function, TPT1/TCTP was
initially named according to its molecular weight as Q23
[1], P21 [2], or P23 [3]. Subsequently, TPT1/TCTP was
characterized as the histamine releasing factor (HRF)
and studied for its extrinsic function in allergy and
inflammation [4–7].
The relevance of TPT1/TCTP to tumorigenesis [8] was
derived from two converging lines of investigation. The
first concerned the function of TSAP6, a direct transcrip-
tional target of the tumor suppressor p53 encoding a 6-
transmembrane domain protein that regulates the cell
cycle, apoptosis, and iron metabolism [9–12]. TPT1/TCTP
was found to interact with TSAP6, which – in turn –
regulated the secretion of TPT1/TCTP via the non-classical
pathway, including exosomes [13,14]. The role of the p53–
TSAP6 axis in regulating protein secretion was further
highlighted [15]. A second line of investigation approached
the issue of tumor reversion by deriving revertant cells
from human leukemia cell lines and solid tumors [16–19].
To trace the molecular events leading to reversion, differ-
ential gene expression between the parental tumor cells
and the revertants was investigated and TPT1/TCTP was
found to represent the most differentially expressedCorresponding author: Telerman, A. (telerman@noos.fr,
adam.telerman@lbpa.ens-cachan.fr).
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that the reduction in TPT1/TCTP levels was indeed re-
sponsible for the reprogramming of cancer cells into rever-
tants that lost most of their malignant phenotype [18,19].
The outlook on TPT1/TCTP acquired an even more
complex dimension when it was found that, in Drosophila,
TPT1/TCTP is epistatic to TSC1 and dRheb in regulation
of the mechanistic target of rapamycin (mTOR) pathway
[20]. In addition, TPT1/TCTP was found to be an upstream
activator of oct4 and nanog in somatic nuclei transplanta-
tion experiments [21]. There seems to be convergent evi-
dence, therefore, for an important role of TPT1/TCTP in
the reprogramming of various phenotypes, a concept
underscored by the wide variety of protein–protein inter-
actions engaged by TPT1/TCTP (Figure 1) that witness or
predict an involvement in diverse processes such as cell
survival, proliferation and growth, inflammation, DNA
damage sensing/repair, and RNA/ribosome/protein biogen-
esis. Some of the characteristics of TPT1/TCTP are remi-
niscent of viral features, such as the highly structured
mRNA that activates the interferon-inducible PKR [22],
the ribonucleoprotein (RNP) particles surrounding this
mRNA [2], the structural similarity between TPT1/TCTP
protein and helicases, the way it antagonizes P53 [23], and
its secretion by cells through exosomes [13,14], as is the
case for HIV [24,25]. In this review, we will focus on
numerous structural, evolutionary, and functional proper-
ties of TPT1/TCTP that highlight the concept that this
protein might sit at the heart of important reprogramming
networks that impact several cellular programs of physio-
logical and pathological relevance.
TPT1/TCTP mRNA activates PKR
Initial attention to TPT1/TCTP, at the beginning of the
1980s, was directed not so much at its protein function, but
rather to the regulation, and to possible functions, of its
mRNA. TPT1/TCTP was originally discovered as a protein
inducible by serum activation of quiescent cells [1]. The fact
that its induction was insensitive to actinomycin D argued
for regulation at the post-transcriptional level [1]. A possi-
ble mechanism for such regulation emerged shortly there-
after, when TPT1/TCTP was identified as one of a small
series of untranslated messengers in a ‘masked state’6/j.tcb.2012.10.002 Trends in Cell Biology xx (2012) 1–10 1
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Figure 1. Schematic representation of the proteins interacting with TPT1/TCTP. Most of these proteins were found by yeast two-hybrid screening (yellow) and for some the
interactions were confirmed by coimmunoprecipitation of overexpressed proteins (blue), subcellular colocalization, Biacore and other assays such as pull-down (pink),
immunoprecipitation of endogenous cellular proteins (green), genetic interactions in murine models (red), use of pharmacological agents (black), or clinical relevance in a
large cohort of breast cancer patients (turquoise). These TPT1/TCTP interactions with other proteins are represented according to seven functionally different categories of
proteins; namely, the P53 axis, cytoskeleton and mitotic machinery, DNA processing and repair, RNA/ribosome and protein biogenesis, other proteins such as the Na, K-
ATPase, antiapoptotic proteins, and GTPase-related proteins. A series of these interactions have been reported (https://usgene.sequencebase.com/patents/US20060140970)
[79] including: Stahtmin/OP18, b2-integrin, DNA helicase SW1/SNF, topoisomerase II a, splicing factor SC35, non structural protein 1 (NS1) of the minute virus of mice, RNA
polymerase II transcription cofactor 4, translation initiation factor 3 (eIF3), ATP synthase DEAE/H RNA helicase, PAI-1 mRNA-binding protein, tRNA nucleotidyl transferase,
and isoleucine t-RNA synthetase.
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masked messengers become active after deproteinization,
a situation reminiscent of the life cycle of viruses.
Although it was understood at the end of the 1980s that
the decay of mRNAs is partially determined by the struc-
ture of their 30 untranslated region (UTR), which folds into
hairpins and functions as a barrier against 30 exonuclease
[26], it was only in 2002 that it was discovered that the
mRNA for TPT1/TCTP is potentially highly structured2[22]. Indeed, the predicted secondary structure of the
TPT1/TCTP mRNA suggests that there are multiple dou-
ble-strand (ds) RNA domains (Figure 2). This finding
allows us to draw another interesting parallel with viruses,
in that dsRNA structures are known to activate the inter-
feron-dependent PKR [27,28], a property shared by the
mRNA of TPT1/TCTP [22].
PKR is one of four kinases known to phosphorylate and
thus inhibit the eukaryotic initiation factor eIF2a, thereby
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Figure 2. Activation of PKR by TPT1/TCTP mRNA. As described for viral double stranded (ds) RNAs [27,28], the mRNA for TCTP activates protein kinase R (PKR) [22], which
is also the case for other mRNAs such as mRNA tropomyosin, mRNA troponin, and mRNA cardiac actin [31]. By adopting a highly structured conformation, TPT1/TCTP and
other cellular mRNAs activate PKR [27]. PKR phosphorylates eukaryotic initiation factor 2 (eIF2a), thereby stopping the protein translation machinery and inhibiting the
translation of TPT1/TCTP. PKR is also directly activated at the transcriptional level by P53 [36].
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tion, one of the major cellular responses comprises the
recognition of viral dsRNA motifs by PKR. This, in turn,
leads to PKR activation and ensuing phosphorylation of
eIF2a. This virus-directed response constitutes only a facet
of a much wider cellular program, because it is known that
some cellular RNAs and endoplasmic reticulum stress can
also activate PKR [29–35]. It was reported that the 30 UTRs
of the mRNAs of tropomyosin, troponin and, cardiac actin
bind and activate PKR [29–31]. In the case of TPT1/TCTP,
although the secondary structures involved have yet to be
precisely mapped, both the 50 and the 30 UTR might assume
ds configurations able to bind/activate PKR [22]. It must be
pointed out, however, that according to the prediction of
RNAfold (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi)
there are almost 1000 mRNAs that could potentially take
a highly structured conformation. Together, these observa-
tions raise the possibility that TPT1/TCTP, like a number
of other cellular proteins, may control protein synthesis by
activating an interferon response. Although this is an
exciting possibility, the physiological significance of these
findings remains to be established. Notably, PKR was
reported to be a direct transcriptional target of p53 [36],
indicating that this tumor suppressor pathway may also be
involved indirectly in the control of protein synthesis and ofTPT1/TCTP expression via this route (Figure 2). Thus, it
seems reasonable to postulate that the presence of highly
structured conformations might be necessary, but not
sufficient, to bind/activate PKR. In turn, this calls for
higher-resolution studies to clarify the mechanism and
the physiological relevance of the control exerted by
TPT1/TCTP mRNA over PKR.
Structure–function analysis of TPT1/TCTP
The structure of TPT1/TCTP was resolved by NMR spec-
troscopy (for the Schizosaccharomyces pombe protein), and
by X-ray crystallography (for the human protein) [37,38].
This analysis revealed three domains that are highly
conserved in TPT1/TCTP throughout phylogeny: (i) a core
of nine b-strands including the short H1 helix; (ii) an a-
helical hairpin formed by two H2–H3 helices; and (iii) a
mobile loop (Figure 3) [37,38]. There is no striking se-
quence homology with any other eukaryotic protein. How-
ever, the H2–H3 hairpin helices of TPT1/TCTP display
both sequence homology and structural similarity with the
H5–H6 helices of the bax-bcl2 family of proteins that are
regulators of apoptosis (Figure 3) [38]. Importantly, TPT1/
TCTP acts as an antiapoptotic protein through a series of
mechanisms [18,38,39], including binding and potentiat-
ing Mcl1 [40,41] and Bclxl [42]. Of note, as in the case of the3
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Figure 3. Structural homologies of TPT1/TCTP. Crystal structure of human TPT1/TCTP in two different orientations (upper and lower panels) [38]. (a) Ribbon representation;
the helices H1, H2, and H3 are in turquoise and the core of nine b-strands (b-C) in ochre. (b) Tube representation of the crystal structure of human TPT1/TCTP. (c) TPT1/TCTP
and Bax. (d) TPT1/TCTP and MSS4. (e) TPT1/TCTP and the RNA helicase laboratory of genetics and physiology 2 (LGP2). For all representations, similar and superimposed
structures are highlighted in red (http://ekhidna.biocenter.helsinki.fi/dali_server/).
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TCTP function as mitochondrial membrane-anchoring
motifs to regulate membrane permeability and cytochrome
C release during apoptosis. A Bax hybrid protein, in which
the H5–H6 helices are replaced by the H2–H3 helices of
TPT1/TCTP, retains its ability to induce apoptosis [38].
Mechanistically, transfection experiments support a model
in which TPT1/TCTP antagonizes apoptosis by inserting4into the mitochondrial membrane and inhibiting Bax
homodimerization [38]. Moreover, this antiapoptotic role
of TPT1/TCTP plays a crucial role in development, since
TPT1/TCTP knockout in mice is embryonically lethal due
to massive apoptosis [38,43].
Despite the lack of major sequence homology to other
proteins, the core domain of TPT1/TCTP displays remark-
able structural similarity with two families of proteins: the
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sor of yeast SEC4 (MSS4) [37]. We have recently searched
for additional TPT1/TCTP protein structure similarities in
other proteins using an in silico approach (http://ekhidna.
biocenter.helsinki.fi/dali_server/) and uncovered a similar-
ity with RNA helicases, such as the ATP-dependent RNA
helicase laboratory of genetics and physiology 2 (LGP2)
(Figure 3).
Methionine-R-sulfoxide reductase B1 protects against
reactive oxygen species (ROS), which are generated during
mitochondrial respiration and promote protein, lipid, and
DNA damage. The high structural similarity between
methionine-R-sulfoxide reductase B1 and TPT1/TCTP
may indicate a common role in protecting cells against
oxidative stress. Conversely, the homology with MSS4 has
drawn much attention. MSS4 is a regulator of intracellular
membrane trafficking that displays relatively low guanine
nucleotide exchange factor (GEF) activity for Rabs. The
similarity between MSS4 and TPT1/TCTP suggests that
TPT1/TCTP could function as a GEF, a possibility that is
further discussed below.
The structural similarity between the core domain of
TPT1/TCTP and the mRNA helicases is striking
(Figure 3). It has not been previously reported and
deserves further comment. The RNA helicases are motor
proteins involved not only in the unwinding of duplex
nucleic acids, but also in protein–RNA interactions, initi-
ation of translation, and ribosome biogenesis. The closest
similarity is with the retinoic acid-inducible gene 1 (RIG-
1)-like receptors (RLRs). There are three RLR members:
RIG-1, melanoma differentiation-associated factor 5
(MDA5), and LGP2 [44], a sensor of viral RNA, particularly
ds viral RNAs [45,46]. RLR members activate signaling
cascades that lead to the production of cytokines, such
as type1 interferons [47]. This sensing of viral infection
is the first barrier provided by the innate immune
system [44]. Together with the previously described ability
of TPT1/TCTP mRNA to activate the interferon-inducible
PKR, these findings further raise the possibility that TPT1/
TCTP exerts its function, at least partly and through a
different mechanism, by modulating interferon-regulated
processes. This possibility warrants further experimental
validation.
TPT1/TCTP and mTOR signaling
The first genetic link between TPT1/TCTP and compo-
nents of the mTOR signaling pathway comes from experi-
ments in flies [20]. The mTOR signaling pathway regulates
diverse processes such as size and cell number by func-
tioning as a sensor and integrator of environmental and
intracellular signals [48]. Upstream of mTOR are nutri-
ents, growth factors and their signaling pathways, energy,
and stress. They ultimately regulate TSC1–TSC2, which
acts as a GTPase-activating protein (GAP) for Rheb. When
Rheb is in its GTP-bound form, it activates mTOR signal-
ing. Whereas a null Drosophila dTCTP mutation is embry-
onically lethal at the first instar stage, knocking down
dTCTP expression causes a reduction in overall eye and
wing size [20] due to a decrease in both cell size and
number. Importantly, dTCTP was shown to be genetically
epistatic to dRheb, Tsc1, and dInr [20].In plants, Arabidopsis thaliana TPT1/TCTP (AtTCTP)
is expressed widely, including during development
[49,50]. Interestingly, AtTCTP regulates the duration of
the cell cycle and thus mitotic but not postmitotic [50]
growth. Although it was suggested that AtTCTP modu-
lates the mTOR pathway, the mechanism remains to be
identified.
The described studies argue that dTCTP is a positive
regulator of the mTOR pathway, raising the question of the
molecular mechanism. One possibility, based on the struc-
tural homology with MSS4, is that TPT1/TCTP might
function as a GEF for Rheb. It was indeed shown that
dTCTP has a weak GEF-like activity for dRheb [20]. These
findings were, however, challenged shortly thereafter [51–
53]. This is perhaps unsurprising, because a similar debate
has surrounded the putative GEF activity of MSS4 itself
[54,55]. In this latter case, the issue was solved recently
when resolution of the crystal structure of MSS4, in com-
plex with Rab8, established the molecular basis of its weak
and unconventional GEF activity for Rab GTPases [56].
Whether TPT1/TCTP is similarly endowed with weak GEF
activity remains to be elucidated. If so, significant GEF
activity in vivo might become apparent only under specific
circumstances in which the protein is either expressed at
high levels or specifically compartmentalized in the prox-
imity of its putative targets, thus reaching a high local
concentration. In this regard, we note that selective acti-
vation of the Rac1-GEF Tiam1 in a highly compartmental-
ized situation (endosomes) was recently demonstrated
[57]. Regardless, the issue of how TPT1/TCTP might exert
control over the mTOR pathway remains open.
TPT1/TCTP in reprogramming: from SCs to tumor
reversion
The nuclei from differentiated cells can be reprogrammed
when transferred into an egg or oocyte [58]. During this
process, oct4 expression increases. Oct4 is a transcription
factor that, when coexpressed with Sox2, c-MYC, and Klf4,
can reprogram differentiated somatic cells into pluripotent
embryo-like SCs. Strikingly, TPT1/TCTP was shown to
regulate oct4 expression during nuclear transfer experi-
ments [21]. Moreover, depletion of TPT1/TCTP reduces the
transcription of both oct4 and nanog in undifferentiated
cells. Of note, TPT1/TCTP interacts with nucleophosmin/
nucleoplasmin family member 1 (Npm1) and decreases
during differentiation of embryonic stem (ES) cells [59–
61]. Npm1 also binds oct4 during interphase in ES cells
and may be involved in the differentiation process.
Tumor cells can undergo reprogramming and lose their
malignant phenotype in a process referred to as tumor
reversion [8]. To understand the molecular basis, rever-
tants were derived from human tumor cells, ranging from
leukemia cell lines to solid tumors [9,16–19,62–64]. These
revertant cells barely formed tumors when injected into
scid/scid mice, whereas the parental malignant cells form
large tumors that rapidly killed the animals. By analyzing
the gene expression profiles, over 300 genes were found to
be differentially expressed between the tumor cells and
revertants, including TPT1/TCTP [18], displaying 248 sig-
nals (equivalent to the amount of mRNA for TPT1/TCTP)
in the tumor cells and only two in the revertant cells. It was5
Box 1. Breast cancer SCs
Increasing evidence suggests that breast tumors, like the normal
mammary gland, are hierarchically organized, containing a minority
of cells (operationally definable as cancer SCs [CSCs]) endowed
with ‘stemness’ properties, such as self-renewal, quiescence,
extended replicative potential, and the ability to generate the
heterogeneous, non-tumorigenic cell populations that constitute
the tumor bulk [70]. Breast CSCs are thought to drive the initiation
and maintenance of tumors, metastasis, and relapse. Selective
elimination of these cells has therefore been proposed as an
effective strategy for eradicating cancer. A better understanding of
the molecular mechanisms regulating normal SC functions, and
how these mechanisms are perturbed in cancer, is therefore vital to
our understanding of breast tumorigenesis and to the development
of more effective breast cancer therapies.
In this context, the tumor suppressor P53 is emerging as a critical
regulator of SC homeostasis in different types of tissues, including
the mammary gland [71]. Increased wild type (WT) p53 activity in
the murine mammary gland leads to aberrant morphogenesis and
reduction of the self-renewal potential of mammary SCs, demon-
strated by serial transplantation experiments [72]. Conversely, the
mammary epithelium of p53-deficient mice contains an increased
number of SCs and displays increased susceptibility to tumorigen-
esis [73,74]. Consistently, it was recently demonstrated that down-
regulation of P53 following ErbB2 oncogene activation in the
mammary epithelium is responsible for the aberrant self-renewal
kinetics displayed by CSCs derived from ErbB2 mammary tumors
[75]. Loss of p53 resulted in increased proliferation, unlimited self-
renewal potential, and a higher frequency of symmetric versus
asymmetric cell divisions in CSCs, compared with their normal
counterparts. Pharmacological restoration of P53 in ErbB2-CSCs
using Nutlin-3, an inhibitor that prevents Mdm2-mediated ubiquiti-
nation and degradation of P53, correlated with restoration of
asymmetric cell division, reduction in the number of CSCs in ErbB2
tumors, and delayed tumor growth. Notably, Nutlin-3 appeared to
selectively target the CSC compartment, because negligible effects
were observed in the bulk tumor cells and the normal mammary
gland. Thus, P53 regulates the polarity of self-renewing divisions of
mouse mammary SCs and loss of p53 promotes symmetric cell
division, leading to expansion of the CSC compartment and tumor
growth. Mechanisms impacting on p53 function are therefore likely
to be involved in the subversion of SC homeostasis in breast
carcinogenesis, as in the reciprocal repressive feedback loop
between p53 and TPT1/TCTP [23]. The use of sertraline and
thioridazine which target TPT1/TCTP and inhibit its function could
lead to a new therapeutic route in cancer treatment [19,23].
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cells allows reorganization into duct-like structures remi-
niscent of normal growth [18]. In line with this observation,
inhibition of TPT1/TCTP expression in v-src-transformed
NIH-3T3 cells results in a massive reversion of the malig-
nant phenotype. To explore the function of TPT1/TCTP, a
search for interacting proteins was performed and it was
observed that TPT1/TCTP binds directly to the translation
elongation factor eEF1A (which is a GTPase) and its
guanine nucleotide exchange factor eEF1Bbeta [65]. This
interaction between TPT1/TCTP and eEF1Bbeta has also
been described by others [66]. TPT1/TCTP preferentially
stabilized the GDP form of eEF1A and impaired the GDP
exchange reaction promoted by eEF1Bbeta, indicating that
TPT1/TCTP has guanine nucleotide dissociation inhibitor
(GDI) activity [65]. This function of TPT1/TCTP as a GDI
has been put forward as an argument against its GEF
activity, but this might be an overinterpretation because
eEF1A is a large G-protein. As mentioned above (Figure 1),
TPT1/TCTP potentially interacts with a large series of
proteins and it is striking to note that half of them are
implicated in DNA damage sensing/repair and RNA/ribo-
some/protein biogenesis, which could be part of the pro-
gram that switches off the malignant phenotype, an issue
that warrants further investigation. This silencing of
TPT1/TCTP, which is required for reprogramming tumor
cells into revertants, raises the possibility that similar
pathways that are at least partly controlled by TPT1/TCTP
are implicated in the reprogramming of ES cells and
cancer cells.
The p53-TPT1/TCTP repressive feedback loop and
‘stemness’
The pleiotropic nature of the biological activities of TPT1/
TCTP is underscored by its ability to interact physically
with an impressive series of protein partners participating
in many different cellular functions [39–42,65,67–69]
(Figure 1). One particularly relevant TPT1/TCTP interac-
tor is the P53 tumor-suppressor protein. Although it was
previously reported [18] that overexpression of P53
resulted in decreased levels of TPT1/TCTP, it was only
recently demonstrated that TPT1/TCTP is a key regulator
of P53 stability and activity [23] with possible conse-
quences on the homeostasis of the SC compartment
[23,70–75] (Box 1). Mechanistically, TPT1/TCTP downre-
gulates P53 by promoting its ubiquitination by the E3-
ligase Mdm2 and subsequent proteasomal degradation
[23] (Figure 4). This function of TPT1/TCTP is dependent
on its ability to antagonize Numb [23], a major cell fate
determinant involved in various developmental programs
[76]. Numb has been shown to form a trimeric complex with
P53 and Mdm2, and to inhibit Mdm2-mediated ubiquiti-
nation of P53, thereby stabilizing P53 levels and activity
[77]. We demonstrated that TPT1/TCTP competes with
Numb for binding to Mdm2, thereby overriding the inhibi-
tory effect of Numb on Mdm2 and promoting P53 ubiqui-
tination [23]. A second major mechanism by which TPT1/
TCTP promotes the proteasomal degradation of P53 is by
directly stabilizing MDM2 and inhibiting its self-ubiquiti-
nation [23]. Interestingly, transcription of the TPT1/
TCTP gene is directly repressed by P53 (Figure 4). These6data indicate that P53 and TPT1/TCTP are engaged in
reciprocal repression.
In vivo, this circuitry was explored by a mouse genetics
approach [23] and received further support from the ana-
lysis of TPT1/TCTP expression in breast cancer patients
(Box 2). In Tpt1/Tctp heterozygous mice, it was observed
that P53 protein levels were readily detectable in virtually
all tissues, in contrast with wt mice in which endogenous
P53 levels are notoriously difficult to detect [23]. This
observation supports a role for Tpt1/Tctp in the control
of P53 stability under physiological conditions in vivo. Note
that this increase in P53 steady-state levels is partly
surprising, because a similar increase was not observed
in Mdm2 heterozygous or even in Mdm2 hypomorphic
mice, which express 30% of endogenous Mdm2 levels. This
may be explained by the fact that P53 and Mdm2 are
engaged in a classical negative feedback loop, whereas
P53 and Tpt1/Tctp are in a reciprocal repression loop.
As a consequence, although even slight differences in
Tpt1/Tctp expression levels are expected to be amplified
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Figure 4. Converging reprogramming networks. TPT1/TCTP–NUMB–MDM2–P53 axis: TPT1/TCTP and P53 are engaged in a reciprocal repressive feedback loop [23]. TPT1/
TCTP promotes MDM2-dependant ubiquitination and degradation of P53. TPT1/TCTP binds and competes with NUMB [23], the latter stabilizing P53 [77]. P53
transcriptionally represses TPT1/TCTP and also activates TSAP6 [10], which regulates the non-classical secretion of proteins and promotes the secretion of TCTP via
exosomes [13]. Furthermore, P53 activates the E3 ligase SIAH [80], which binds to NUMB and promotes its degradation. TPT1/TCTP–mTOR: Drosophila TPT1/TCTP
regulates the mTOR pathway by acting as a guanine nucleotide exchange factor (GEF)-like molecule for Rheb [20]. Alternatively, TPT1/TCTP could activate mTOR by a
different mechanism. P53 is a negative regulator of the mTOR pathway [81]. TPT1/TCTP-oct4-nanog: TPT1/TCTP is an upstream activator of oct4 and nanog in nuclear
reprogramming [21]. Importantly oct4, when coexpressed with Sox2, c-MYC, and Klf4 in mouse embryonic and adult fibroblasts, reprograms them into induced pluripotent
stem cells [82,83]. The transcription of nanog is repressed by P53 [84]. Numb–Notch–Nodal: the cell fate determinant Numb negatively regulates Notch [76]. Previous
experiments showed that repression of Nodal expression is instrumental in reverting the malignant phenotype of melanoma cells [85] and recent evidence indicates that
nodal is regulated by Notch in these processes [86]. Altogether, converging evidence points toward a central role for TPT1/TCTP in different reprogramming networks.
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Mdm2 levels will be compensated instead by the negative
feedback loop (Figure 4). Importantly, not only P53 basal
levels are elevated in Tpt1/Tctp heterozygous thymocytes,Box 2. The TPT1/TCTP–P53 axis in breast cancer patients
The TPT1/TCTP–P53 axis is also relevant to human breast cancer. In
a cohort of 508 breast cancer patients, high TPT1/TCTP status
correlated with clinical and pathological parameters of aggressive
disease, such as a poor degree of differentiation, high tumor grade
(G3), high proliferative activity, and negative estrogen receptor
expression [23]. High TPT1/TCTP status was also an independent
predictor of poor prognosis in these patients. TPT1/TCTP over-
expression was frequently associated with a mutated p53 status, as
expected based on the evidence that TPT1/TCTP is a negative
transcriptional target of P53 [23]. This argues that, when p53 is
dysfunctional due to primary inactivating mutations, the ensuing
overexpression of TPT1/TCTP most likely represents a major event
contributing to carcinogenesis. It is therefore not surprising that the
negative regulation of P53 by TPT1/TCTP is counteracted by another
cancer-relevant mechanism, namely the Numb/p53 circuitry, which
is crucial sustaining p53 tumor-suppressor activity [77,87]. Interest-
ingly, the biologically aggressive phenotype of TPT1/TCTP-over-
expressing tumors is analogous to the clinically aggressive behavior
of Numb-deficient breast tumors, in which deregulated Mdm2-
dependent degradation of P53 is also observed [77,87].but irradiation (IR)-induced P53 stabilization is more pro-
nounced in these cells, leading to increased P53 transcrip-
tional activity and P53-dependent apoptosis [23]. These
data demonstrate that Tpt1/Tctp haploinsufficiency sen-
sitizes to P53-dependent apoptosis in vivo and therefore
identify Tpt1/Tctp as a critical rate-limiting factor in the
control of P53 stability and activity in response to genotoxic
stress [23].
The consequences of the subversion of TPT1/TCTP-cen-
tered regulations were analyzed in breast cancer. TPT1/
TCTP was identified, via a comparative global transcrip-
tome analysis of purified normal human mammary SCs, as
one of the molecular traits characterizing the identity of
normal human mammary SCs [78]. Direct immunofluores-
cence analysis of TPT1/TCTP expression confirmed the
association of TPT1/TCTP with the normal human mam-
mary SC compartment and its downregulation in differen-
tiating progenitors [23]. These findings suggest that TPT1/
TCTP might be involved in the homeostasis of the mam-
mary SC compartment, and – more specifically – that its
downregulation is a prerequisite for the correct progres-
sion of precursors through the morphogenetic program. A
corollary of this idea is that TPT1/TCTP expression must
be tightly temporally and spatially regulated throughout7
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bly affecting the normal dynamics of the SC compartment.
The first evidence in this direction came from the demon-
stration that silencing TPT1/TCTP expression in breast
cancer cell lines (MCF7 and T47D) reverted the morpho-
genetically aberrant structures formed by these cells in 3D
Matrigel cultures, restoring a growth pattern reminiscent
of the outgrowths generated by normal mammary epithe-
lial cells [18]. In addition, silencing of TPT1/TCTP in
mouse mammary epithelial tumor cells derived from
ErbB2 transgenic mice decreased the ability of these cells
to generate mammospheres, an assay that measures the
intrinsic SC content of a given epithelial cell population
[23]. This effect of TPT1/TCTP on cancer SC self-renewal
was accompanied by an increase in P53 levels, arguing that
TPT1/TCTP influences SC function via the liaison with
P53. Corroborating this notion, pharmacological inhibition
of TPT1/TCTP using sertraline and thioridazine also
resulted in increased p53 levels by counteracting Mdm2-
mediated ubiquitination of p53 and reduced the mammo-
sphere-forming efficiency, thus providing stringent evi-
dence for the existence of a TPT1/TCTP–p53 axis in the
regulation of cancer SC self-renewal [23].
Concluding remarks
The sum of the reviewed evidence, which does not exhaust
the multiplicity of biological processes in which TPT1/
TCTP is involved, argues that it sits at the heart of a
number of programs of physiological relevance that control
the modalities of cell growth in various contexts: from
development to nutrient homeostasis, to stress responses
and apoptosis, to self-renewal in SCs. Alterations of TPT1/
TCTP might therefore play a central role in cancer, as
supported by increasing biological and molecular evidence.
In this regard, we find particularly interesting observa-
tions that TPT1/TCTP-centered programs, involving regu-
lation of the tumor suppressor p53, are involved in both
subversion of the cancer SC compartment and the program
of tumor reversion, arguing that the biological foundations
of the latter might be represented by some form of molecu-
lar ‘cure’ of aberrant modalities of self-renewal of cancer
SCs.
TPT1/TCTP has emerged as a critical survival factor
and a regulator of cell fate determination. TPT1/TCTP
regulates many different biological processes, all of which
may converge to a limited set of key events that control
stemness, pluripotency, and tumor reversion (Figure 4). In
cancer, TPT1/TCTP could have an oncogenic function.
Numerous features argue in favor of this possibility, in-
cluding promoting cell growth, activating components of
the mTOR pathway, inhibiting Bax homodimerization
and apoptosis, antagonizing P53, and being expressed
in aggressive breast cancers [20,23,38]. However, its over-
expression in transgenic mice does not induce or favor
tumor formation [6,69]. In addition, TPT1/TCTP mRNA
is likely to activate PKR, which is in turn critical for the
tumor suppressor function of P53 [36]. Although this
function is not ascribable directly to TPT1/TCTP as a
protein, it supports the notion that its increased transcrip-
tion/expression might be part of tumor-suppressor circuit-
ries. Maybe, like one of its protein partners, NPM18[59–61], TPT1/TCTP combines both a tumor suppressive
and an oncogenic activity that results in context-depen-
dent cancer phenotypes. A recurrent theme is that only
when TPT1/TCTP levels are decreased, notably in cancer,
can cells be reprogrammed. Thus, TPT1/TCTP has the
characteristics of a checkpoint – a switch necessary for
reprogramming. The conservation of the TPT1/TCTP-con-
verging networks (Figure 4) through phylogeny further
underscores their relevance. Deciphering how all these
functions are integrated and which biochemical and mo-
lecular mechanisms underscore their execution is the
challenge lying ahead of us.
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